中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(4): 659-664

Micro-elimination of hepatitis C virus infection in the hemodialysis population

DOI: 10.12449/JCH240403

  • Department of Nephrology，Peking University People’s Hospital，Beijing 100044，China

More Information
  • Corresponding author: ZUO Li， zuoli@bjmu.edu.cn （ORCID： 0000-0002-7340-5995）
  • Received Date: 2024-03-02
  • Accepted Date: 2024-03-20
  • Published Date: 2024-04-25
    Abstract
  • The hemodialysis population is increasing year by year in China. Due to the specific nature of hemodialysis treatment， the prevalence and incidence rates of hepatitis C virus （HCV） infection in hemodialysis patients are much higher than the general population. In order to achieve the WHO’s initiative to eliminate HCV by 2030 and realize the micro-elimination of HCV in the hemodialysis population， standard infection control and hand hygiene procedures should be implemented to cut off the route of iatrogenic infection， especially to prevent the outbreak of HCV infection in hemodialysis centers. Screening for HCV infection should be conducted for patients newly admitted to the hemodialysis center or transferred to another hemodialysis center， and regular screening should be conducted for patients receiving maintenance hemodialysis to identify new HCV infections in the early stage. It is also necessary to collaborate with specialists and provide direct-acting antiviral therapy for hemodialysis patients with HCV infection.

     

    • FullText(HTML)
    • References(20)
  • [1]
    JADOUL M, BIEBER BA, MARTIN P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients[J]. Kidney Int, 2019, 95( 4): 939- 947. DOI: 10.1016/j.kint.2018.11.038.
    [2]
    GOODKIN DA, BIEBER B, JADOUL M, et al. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis[J]. Clin J Am Soc Nephrol, 2017, 12( 2): 287- 297. DOI: 10.2215/CJN.07940716.
    [3]
    Breakthrough One Million/Latest Data on Dialysis Patients in China Released, Heavyweight[EB/OL].( 2023-07-24). https://www.sohu.com/a/705638529_408003. https://www.sohu.com/a/705638529_408003

    突破百万/中国透析患者最新数据新鲜出炉, 重磅![EB/OL].( 2023-07-24). https://www.sohu.com/a/705638529_408003. https://www.sohu.com/a/705638529_408003
    [4]
    GAN LY, WANG DY, BIEBER B, et al. Hepatitis C prevalence, incidence, and treatment in Chinese hemodialysis patients: Results from the dialysis outcomes and practice patterns study-China(2019-21)[J]. Front Med, 2022, 9: 910840. DOI: 10.3389/fmed.2022.910840.
    [5]
    MARC L, MIHAESCU A, LUPUSORU R, et al. Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy-experience of 10 Romanian HD centers[J]. Int Urol Nephrol, 2023, 55( 11): 2951- 2958. DOI: 10.1007/s11255-023-03587-0.
    [6]
    MIAO XQ, WANG CR, ZENG C, et al. Prevention and control of hepatitis C virus outbreak event in hemodialysis room[J]. Chin J Infect Contr, 2020, 19( 12): 1140- 1144. DOI: 10.12138/j.issn.1671-9638.20206202.

    缪兴全, 王超然, 曾翠, 等. 血液透析室丙型肝炎病毒暴发事件的分析与防控[J]. 中国感染控制杂志, 2020, 19( 12): 1140- 1144. DOI: 10.12138/j.issn.1671-9638.20206202.
    [7]
    Notice of the National Health Commission on Hepatitis C infection in hemodialysis patients in Dongtai People's Hospital of Jiangsu Province[R/OL]. Network of State Administration and medical administration.( 2019-06-18). http://www.nhc.gov.cn/yzygj/s3594/201906/2d47e45677fe4ff2b12e5afd3eb04891.shtml. http://www.nhc.gov.cn/yzygj/s3594/201906/2d47e45677fe4ff2b12e5afd3eb04891.shtml

    国家卫生健康委关于江苏省东台市人民医院发生血液透析患者感染丙肝事件有关情况的通报[R/OL]. 医政医管网.( 2019-06-18). http://www.nhc.gov.cn/yzygj/s3594/201906/2d47e45677fe4ff2b12e5afd3eb04891.shtml. http://www.nhc.gov.cn/yzygj/s3594/201906/2d47e45677fe4ff2b12e5afd3eb04891.shtml
    [8]
    CAMPO DS, XIA GL, DIMITROVA Z, et al. Accurate genetic detection of hepatitis C virus transmissions in outbreak settings[J]. J Infect Dis, 2016, 213( 6): 957- 965. DOI: 10.1093/infdis/jiv542.
    [9]
    Centers for Disease Control and Prevention. Health care-Associated Hepatitis B and C Outbreaks(≥2 cases) Reported to the CDC 2008-2019[S/OL]. Atlanta, GA: Centers for Disease Control and Prevention; 2020. https://www.cdc.gov/hepatitis/outbreaks/healthcarehepoutbreaktable.htm. https://www.cdc.gov/hepatitis/outbreaks/healthcarehepoutbreaktable.htm
    [10]
    MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology, 2013, 57( 4): 1333- 1342. DOI: 10.1002/hep.26141.
    [11]
    GIROU E, CHEVALIEZ S, CHALLINE D, et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit[J]. Clin Infect Dis, 2008, 47( 5): 627- 633. DOI: 10.1086/590564.
    [12]
    CARRILHO FJ, MORAES CR, PINHO JRR, et al. Hepatitis B virus infection in Haemodialysis Centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology[J]. BMC Public Health, 2004, 4: 13. DOI: 10.1186/1471-2458-4-13.
    [13]
    PETROSILLO N, GILLI P, SERRAINO D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis[J]. Am J Kidney Dis, 2001, 37( 5): 1004- 1010. DOI: 10.1016/s0272-6386(05)80017-4.
    [14]
    Disease Kidney: Improving Global Outcomes Hepatitis C Work Group. KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int, 2022, 102( 6S): S129- S205. DOI: 10.1016/j.kint.2022.07.013.
    [15]
    Standard Operating Procedures for Blood Purification(2021). National Health Commission Office‍〔2021〕‍No.552[S/OL].( 2021-11-08). http://www.nhc.gov.cn/yzygj/s7659/202111/6e25b8260b214c55886d6f0512c1e53f.shtml. http://www.nhc.gov.cn/yzygj/s7659/202111/6e25b8260b214c55886d6f0512c1e53f.shtml

    血液净化标准操作规程(2021版). 国卫办医函‍〔2021〕‍552号[S/OL].( 2021-11-08). http://www.nhc.gov.cn/yzygj/s7659/202111/6e25b8260b214c55886d6f0512c1e53f.shtml. http://www.nhc.gov.cn/yzygj/s7659/202111/6e25b8260b214c55886d6f0512c1e53f.shtml
    [16]
    FISSELL RB, BRAGG-GRESHAM JL, WOODS JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS[J]. Kidney Int, 2004, 65( 6): 2335- 2342. DOI: 10.1111/j.1523-1755.2004.00649.x.
    [17]
    SAAB S, MARTIN P, BREZINA M, et al. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis[J]. Am J Kidney Dis, 2001, 37( 2): 308- 315. DOI: 10.1053/ajkd.2001.21294.
    [18]
    HUANG CF, DAI CY, WANG CW, et al. Therapy as prevention toward HCV elimination in maintenance hemodialysis: A multi-center, prospective cohort study[J]. Clin Kidney J, 2023, 16( 12): 2429- 2436. DOI: 10.1093/ckj/sfad138.
    [19]
    LEE JJ, CHANG JM, YANG LJ, et al. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010-2018[J]. J Formos Med Assoc, 2022, 121( Suppl 1): S73- S81. DOI: 10.1016/j.jfma.2021.12.019.
    [20]
    OKUBO T, ATSUKAWA M, TSUBOTA A, et al. Epidemiological survey of patients with hemodialysis complicated by hepatitis C in Japan[J]. Ther Apher Dial, 2019, 23( 1): 44- 48. DOI: 10.1111/1744-9987.12747.
    • Relative Articles

  • Relative Articles

    [1]Jian LI, Fuzhen WANG, Zhongdan CHEN, Jinlei QI, Ailing WANG, Fanghui ZHAO, Yuanyuan KONG, Jing SUN, Jiaqi KANG, Zundong YIN, Zhongfu LIU, Jidong JIA, Yu WANG. Research advances in the disease burden of viral hepatitis in China[J]. Journal of Clinical Hepatology, 2025, 41(2): 221-227. doi: 10.12449/JCH250205
    [2]Jian LI, Zhongfu LIU. Advances， achievements， and challenges in action to eliminate hepatitis C as a public health threat in China[J]. Journal of Clinical Hepatology, 2025, 41(2): 216-220. doi: 10.12449/JCH250204
    [3]Yu WANG. Public health management strategies： A pathway to eliminating viral hepatitis threats[J]. Journal of Clinical Hepatology, 2025, 41(2): 201-204. doi: 10.12449/JCH250201
    [4]Li ZHANG, Peng HU. Hepatitis C virus infection and organ transplantation[J]. Journal of Clinical Hepatology, 2024, 40(4): 665-671. doi: 10.12449/JCH240404
    [5]Haiying ZHANG, Huiying RAO, Hongsong CHEN. Current status of hepatitis C virus infection and progress in its elimination in China[J]. Journal of Clinical Hepatology, 2024, 40(4): 649-653. doi: 10.12449/JCH240401
    [6]Hongqiao ZHENG, Ailing WANG. Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide[J]. Journal of Clinical Hepatology, 2024, 40(11): 2152-2157. doi: 10.12449/JCH241104
    [7]Zujiang YU, Ye ZHANG, Jianqi LIAN. Application of sofosbuvir in HCV-infected patients with end-stage renal disease undergoing hemodialysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1193-1196. doi: 10.3969/j.issn.1001-5256.2021.05.045
    [8]Jiang Hua, Zhou Min, Xue BoYu, Wan LingFeng, Sun LiXia. Research progress in chronic kidney disease with hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2015, 31(11): 1912-1915. doi: 10.3969/j.issn.1001-5256.2015.11.039
    [9]Wu ShaoHong, Gan JianHe, Huang XiaoPing, Lin Hua, Lu NianFang, Wu JiangQuan, Zheng RuiQiang. Clinical effect of albumin dialysis combined with plasma perfusion in treatment of liver failure[J]. Journal of Clinical Hepatology, 2014, 30(5): 434-437. doi: 10.3969/j.issn.1001-5256.2014.05.013
    [10]Zhu FuSheng, Qin YuJie, Cheng ZhenJiang, Jiang PeiRong, Zhang LingHui. The impact of HBV/HCV coinfection on HBV DNA levels and the severity of liver diseases in HBV-infected patients undergoing hemodialysis[J]. Journal of Clinical Hepatology, 2013, 29(2): 136-137+141.
    [11]Wang YuMing, Cheng Lin. Recent perspectives of Chinese medicine-based therapy for hepatitis B and C virus infection[J]. Journal of Clinical Hepatology, 2012, 28(11): 872-876.
    [12]Nie HongMing, Chen JianJie, Dong HuiLin, Yang YuQi, Wang ChengBao, Li HongDing, Chen YiYun, Gao YueQiu. Analysis of clinical characteristics of the infection of HCV genotype 1 and non-genotype 1 in China[J]. Journal of Clinical Hepatology, 2012, 28(6): 439-442.
    [13]Chen QingMei, Tang Ni. The research progress of hepatitis C virus non-structural protein 5A[J]. Journal of Clinical Hepatology, 2012, 28(5): 398-401.
    [14]Yin Xiao, Wen Bo, Tan WenJie. Progress in the development and immunogenicity improvement of DNA vaccine against chronic HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 32-35.
    [15]Tian Di, Xu XiaoYuan. Treatment of hepatitis C virus infection in HIV/HCV co-infected patients[J]. Journal of Clinical Hepatology, 2011, 27(5): 540-544.
    [16]Gao LuHua, Nie QingHe. Detection of hepatitis C virus in the supernatant of human placenta trophoblastic cells and cell lysates[J]. Journal of Clinical Hepatology, 2011, 27(12): 1296-1300.
    [17]Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.
    [18]Yan Yan, Xiu BingShui, Yin JiMing, Zhang HeQiu, Li Zhuo. Evaluation of cross-reactive antibody response to hypervariable region 1 of hepatitis C virus[J]. Journal of Clinical Hepatology, 2011, 27(8): 818-820.
    [19]Qi ZhongTian. Hepatitis C virus infection and its therapeutic drugs[J]. Journal of Clinical Hepatology, 2011, 27(1): 15-18+27.
    [20]Yang RuiFeng, Wei Lai. Detection of hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 1-7.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 21.9 %FULLTEXT: 21.9 %META: 65.7 %META: 65.7 %PDF: 12.3 %PDF: 12.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.6 %其他: 7.6 %其他: 0.6 %其他: 0.6 %China: 0.4 %China: 0.4 %Matale: 0.5 %Matale: 0.5 %Tiruchi: 0.1 %Tiruchi: 0.1 %上海: 4.7 %上海: 4.7 %东莞: 0.2 %东莞: 0.2 %乌鲁木齐: 0.2 %乌鲁木齐: 0.2 %伊利诺伊州: 0.2 %伊利诺伊州: 0.2 %佛山: 0.2 %佛山: 0.2 %信阳: 0.1 %信阳: 0.1 %六安: 0.2 %六安: 0.2 %北京: 4.2 %北京: 4.2 %南京: 0.1 %南京: 0.1 %南宁: 0.1 %南宁: 0.1 %南昌: 0.2 %南昌: 0.2 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %咸宁: 0.1 %咸宁: 0.1 %咸阳: 0.1 %咸阳: 0.1 %哈密: 0.2 %哈密: 0.2 %哥伦布: 0.1 %哥伦布: 0.1 %墨尔本: 0.6 %墨尔本: 0.6 %大连: 0.2 %大连: 0.2 %天津: 0.2 %天津: 0.2 %孟买: 0.1 %孟买: 0.1 %宁波: 0.2 %宁波: 0.2 %安塔利亚: 0.1 %安塔利亚: 0.1 %安康: 0.2 %安康: 0.2 %宣城: 0.4 %宣城: 0.4 %密蘇里城: 0.1 %密蘇里城: 0.1 %巴音郭楞: 0.2 %巴音郭楞: 0.2 %布加勒斯特: 0.1 %布加勒斯特: 0.1 %常州: 0.4 %常州: 0.4 %常德: 0.2 %常德: 0.2 %广州: 0.6 %广州: 0.6 %开罗: 0.1 %开罗: 0.1 %张家口: 2.8 %张家口: 2.8 %成都: 1.0 %成都: 1.0 %昆明: 0.7 %昆明: 0.7 %晋城: 0.1 %晋城: 0.1 %朝阳: 0.1 %朝阳: 0.1 %杭州: 1.2 %杭州: 1.2 %株洲: 0.2 %株洲: 0.2 %武汉: 2.3 %武汉: 2.3 %沈阳: 0.1 %沈阳: 0.1 %济南: 2.0 %济南: 2.0 %海得拉巴: 0.2 %海得拉巴: 0.2 %海防: 0.1 %海防: 0.1 %深圳: 0.2 %深圳: 0.2 %温州: 0.2 %温州: 0.2 %湘潭: 0.1 %湘潭: 0.1 %玉溪: 0.2 %玉溪: 0.2 %班加罗尔: 0.1 %班加罗尔: 0.1 %眉山: 0.1 %眉山: 0.1 %福州: 0.1 %福州: 0.1 %科泽科德: 0.2 %科泽科德: 0.2 %绍兴: 0.1 %绍兴: 0.1 %芒廷维尤: 27.6 %芒廷维尤: 27.6 %芝加哥: 3.9 %芝加哥: 3.9 %苏州: 0.2 %苏州: 0.2 %莫斯科: 0.6 %莫斯科: 0.6 %菏泽: 0.6 %菏泽: 0.6 %葫芦岛: 0.1 %葫芦岛: 0.1 %衡水: 0.5 %衡水: 0.5 %衡阳: 0.2 %衡阳: 0.2 %西宁: 7.6 %西宁: 7.6 %西安: 0.4 %西安: 0.4 %西雅图: 0.6 %西雅图: 0.6 %诺沃克: 0.2 %诺沃克: 0.2 %赣州: 0.1 %赣州: 0.1 %运城: 1.1 %运城: 1.1 %遂宁: 0.4 %遂宁: 0.4 %遵义: 0.4 %遵义: 0.4 %郑州: 0.2 %郑州: 0.2 %重庆: 0.5 %重庆: 0.5 %铁岭: 0.1 %铁岭: 0.1 %长春: 14.9 %长春: 14.9 %长沙: 0.9 %长沙: 0.9 %长治: 0.5 %长治: 0.5 %青岛: 0.2 %青岛: 0.2 %黄冈: 0.1 %黄冈: 0.1 %黔南: 0.1 %黔南: 0.1 %其他其他ChinaMataleTiruchi上海东莞乌鲁木齐伊利诺伊州佛山信阳六安北京南京南宁南昌卡纳塔克咸宁咸阳哈密哥伦布墨尔本大连天津孟买宁波安塔利亚安康宣城密蘇里城巴音郭楞布加勒斯特常州常德广州开罗张家口成都昆明晋城朝阳杭州株洲武汉沈阳济南海得拉巴海防深圳温州湘潭玉溪班加罗尔眉山福州科泽科德绍兴芒廷维尤芝加哥苏州莫斯科菏泽葫芦岛衡水衡阳西宁西安西雅图诺沃克赣州运城遂宁遵义郑州重庆铁岭长春长沙长治青岛黄冈黔南

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (532) PDF downloads(98) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2784]YesterdayPV[4482]TodayIP[93]TodayPV[146]Online[54]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return